Advertisement

The Second Edition Bethesda System for Reporting Thyroid Cytopathology

  • Rana S. HodaEmail author
Chapter
  • 515 Downloads

Abstract

  • The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), a uniform and standardized reporting system for thyroid fine needle aspiration (FNA), was originally established in 2009 and updated in 2017. The system is widely accepted in the United States and globally.

  • It is specifically designed for the reporting of thyroid follicular and C-cell–derived lesions based on clearly outlined diagnostic criteria.

Keywords

The 2017 Bethesda system for reporting thyroid cytopathology TBSRTC Papillary thyroid carcinoma Risk of malignancy Noninvasive follicular thyroid neoplasm with papillary-like nuclear features Recommended management Fine needle aspiration Surgery American Thyroid Association (ATA) Indeterminate diagnostic categories LBP 

Suggested Reading

  1. 1.
    Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology; definitions, criteria, and explanatory notes. 2nd ed. Cham: Springer International Publishing AG; 2018.CrossRefGoogle Scholar
  2. 2.
    Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology II. Acta Cytol. 2016;60:397–8.CrossRefGoogle Scholar
  3. 3.
    Bychkov A, Keelawat S, Agarwal S, Jain D, Jung CK, Hong S, et al. Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries. Pathology. 2018;50:411–7.  https://doi.org/10.1016/j.pathol.2017.11.088.CrossRefPubMedGoogle Scholar
  4. 4.
    Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27:1341–6.  https://doi.org/10.1089/thy.2017.0500.CrossRefPubMedGoogle Scholar
  5. 5.
    Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19:1159–65.  https://doi.org/10.1089/thy.2009.0274.CrossRefPubMedGoogle Scholar
  6. 6.
    Crippa S, Mazzucchelli L, Cibas ES, Ali SZ. The Bethesda system for reporting thyroid fine-needle aspiration specimens. Am J Clin Pathol. 2010;134:343–4.; author reply 345.  https://doi.org/10.1309/AJCPXM9WIRQ8JZBJ.CrossRefPubMedGoogle Scholar
  7. 7.
    Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in the Bethesda system for reporting thyroid cytopathology. Cancer Cytopathol. 2016;124:181–7.CrossRefGoogle Scholar
  8. 8.
    Guo A, Kaminoh Y, Forward T, Schwartz FL, Jenkinson S. Fine needle aspiration of thyroid nodules using the Bethesda system for reporting thyroid cytopathology: an institutional experience in a rural setting. Int J Endocrinol. 2017;2017:9601735.  https://doi.org/10.1155/2017/9601735.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ha EJ, Na DG, Moon WJ, Lee YH, Choi N. Diagnostic performance of ultrasound-based risk-stratification systems for thyroid nodules: comparison of the 2015 American Thyroid Association Guidelines with the 2016 Korean Thyroid Association/Korean Society of Thyroid Radiology and 2017 American Congress of Radiology Guidelines. Thyroid. 2018;28:1532–7.  https://doi.org/10.1089/thy.2018.0094. Erratum in: Thyroid. 2019;29:159.CrossRefPubMedGoogle Scholar
  10. 10.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.  https://doi.org/10.1002/cncr.30360.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hoda RS. Non-gynecologic cytology on liquid-based preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007;35:621–34.CrossRefGoogle Scholar
  12. 12.
    Hoda RS, VandenBussche C, Hoda SA. Diagnostic liquid-based cytology. New York: Springer; 2017.CrossRefGoogle Scholar
  13. 13.
    Kim SD, Han SH, Jeong WJ, Kim H, Ahn SH. Differences in clinical features between subcategories of “atypia/follicular lesion of undetermined significance”. Endocr Pathol. 2017;28:247–52.  https://doi.org/10.1007/s12022-017-9486-3.CrossRefPubMedGoogle Scholar
  14. 14.
    Krane JF, Alexander EK, Cibas ES, Barletta JA. Coming to terms with NIFTP: a provisional approach for cytologists. Cancer Cytopathol. 2016;124:767–72.  https://doi.org/10.1002/cncy.21769.CrossRefPubMedGoogle Scholar
  15. 15.
    Lau RP, Paulsen JD, Brandler TC, Liu CZ, Simsir A, Zhou F. Impact of the reclassification of “noninvasive encapsulated follicular variant of papillary thyroid carcinoma” to “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” on the Bethesda system for reporting thyroid cytopathology: a large academic institution’s experience. Am J Clin Pathol. 2017;149:50–4.  https://doi.org/10.1093/ajcp/aqx136.CrossRefPubMedGoogle Scholar
  16. 16.
    Legesse T, Parker L, Heath J, Staats PN. Distinguishing noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) from classic and follicular variant of papillary thyroid carcinomas based on cytologic features. J Am Soc Cytopathol. 2019;8:11–7.  https://doi.org/10.1016/j.jasc.2018.07.004.CrossRefPubMedGoogle Scholar
  17. 17.
    Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9.CrossRefGoogle Scholar
  18. 18.
    Nusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, et al. The Bethesda system for reporting thyroid cytopathology: proposed modifications and updates for the second edition from an international panel. Acta Cytol. 2016;60:399–405.CrossRefGoogle Scholar
  19. 19.
    Park VY, Lee HS, Kim EK, Kwak JY, Yoon JH, Moon HJ. Frequencies and malignancy rates of 6-tiered Bethesda categories of thyroid nodules according to ultrasound assessment and nodule size. Head Neck. 2018;40:1947–54.  https://doi.org/10.1002/hed.25179.CrossRefPubMedGoogle Scholar
  20. 20.
    Poller DN, Baloch ZW, Fadda G, Johnson SJ, Bongiovanni M, Pontecorvi A, et al. Thyroid FNA: new classifications and new interpretations. Cancer Cytopathol. 2016;124:457–66.  https://doi.org/10.1002/cncy.21703.CrossRefPubMedGoogle Scholar
  21. 21.
    Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol. 2016;17:370–95.  https://doi.org/10.3348/kjr.2016.17.3.370.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, et al. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015;25:987–92.  https://doi.org/10.1089/thy.2014.0612.CrossRefPubMedGoogle Scholar
  23. 23.
    Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14:587–95.  https://doi.org/10.1016/j.jacr.2017.01.046.CrossRefPubMedGoogle Scholar
  24. 24.
    Vivero M, Renshaw AA, Krane JF. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. Cancer. 2017;125:534–43.  https://doi.org/10.1002/cncy.21858.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.CBLPathRye BrookUSA

Personalised recommendations